1. Field of the Invention
Embodiments of the present invention generally relate to prevention of abnormal breathing sounds (e.g., snoring), adverse consequences, illness or death in persons due to partial or complete blockage of the upper airway.
2. Description of the Related Art
A common and potentially serious disorder in humans involves involuntary closure of the airway during sleep. This disorder is known as “sleep-disordered breathing” or “obstructive sleep apnea” (OSA). In persons with OSA, there is involuntary closure or reduction in caliber of a portion of the airway that connects the atmosphere to the lungs. The upper portion of the airway (the “upper airway”) consists of two passageways, the nasal airway and the oral airway. These two passageways merge to become a single passageway. Portions of the upper airway just behind the tongue are known as the soft palate, the pharynx, the hypopharynx, etc.
In persons affected by OSA, closure, reduction in patency or increased airflow resistance of the upper airway occurs during sleep, due to a combination of physiological changes associated with sleep (including relaxation of muscles) and the anatomy of the upper airway (which is generally smaller or more crowded than in normal individuals). In persons prone to sleep apnea, a portion or portions of the muscular walls of the upper airway may become narrow or collapse, leading to reduction in airflow (“hypopnea”), cessation of airflow (“apnea”), increase in airflow turbulence or increased resistance to airflow within the airway. In the instance of collapse, the upper airway is blocked, breathing stops, air movement to the lungs ceases, and the oxygen level in the blood tends to decrease. As a response to this process (or to less severe manifestations, such as hypopneas or increased airway resistance), a brief arousal usually occurs in the brain. As a consequence of the brief arousal, the muscle tone in the walls of the upper airway returns to waking levels, and the airway abnormality is corrected—i.e. airway resistance and patency return to normal levels.
Generally, following each event, the patient returns to sleep, until another partial or complete upper airway collapse occurs and the process repeats itself. Depending on the severity in an individual case, the number of events may range from a few per hour of sleep to more than 100 events per hour of sleep. This process disrupts normal sleep. As a consequence, patients typically suffer from the effects of sleep deprivation. Such effects may include daytime drowsiness, tiredness or fatigue, difficulties with mental concentration or memory, mood changes, reductions in performance or increases in mistakes, and increased risk of accidents. Additionally, OSA is known to increase the risk of development of other medical problems
Snoring is a mild form of sleep-disordered breathing in which increased airflow turbulence occurs. The snoring sounds result from tissue vibration within the nasal or oral airway. While snoring has been traditionally regarded as a social or cosmetic problem, recent studies suggest that snoring may be linked to the development of health problems, including high blood pressure.
Airway closure during sleep generally occurs at one or both of two levels in the upper airway: the soft palate and the hypopharynx (base of the tongue). At either level, the anterior tissue can collapse against the posterior pharyngeal wall, which makes up the rear wall of the throat. Additionally, the side (lateral) walls of the upper airway can collapse inward partially, or completely against each other. The lateral walls of the airway are susceptible to collapse in many patients with obstructive sleep apnea and other forms of sleep-related breathing disorders. In these cases, prevention of collapse of the airway only in the anterior-posterior dimension is insufficient to maintain normal airway patency. Even after extensive airway surgery for sleep apnea (which primarily addresses the anterior-posterior dimension of the airway), the patient may continue to have problems with breathing during sleep, due to lateral wall collapse or dysfunction.
Several types of treatment are available for obstructive sleep apnea and other sleep-related breathing disorders. The most common treatment consists of an air pressure delivery system that applies greater than atmospheric pressure to all walls of the upper airway to reduce the potential for full or partial collapse. Many people have difficulty using this device or prefer not to use it for various reasons. Also, surgical reconstruction of the airway or dental devices may be used. These treatments, however, often fail to treat the problem adequately.
Accordingly, a need exists in the art for an improved method and system for treating sleep apnea and other sleep-related breathing disorders.
Embodiments of the present invention are generally directed to a system for treating sleep-related breathing disorders. In one embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall, and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway.
In another embodiment, the system includes a first magnetically susceptible material attached to a left lateral pharyngeal wall and a second magnetically susceptible material attached to a right lateral pharyngeal wall. The second magnetically susceptible material is positioned opposite the first magnetically susceptible material across an upper airway. The system further includes a first magnet disposed outside the body and lateral to the first magnetically susceptible material, and a second magnet disposed outside the body and lateral to the second magnetically susceptible material.
In yet another embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway. The system further includes a third magnet disposed inside the upper airway directly across from the first magnet and a fourth magnet disposed inside the upper airway directly across from the second magnet.
The following detailed description makes reference to the accompanying drawings, which are now briefly described.
While the invention is described herein by way of example for several embodiments and illustrative drawings, those skilled in the art will recognize that the invention is not limited to the embodiments or drawings described. It should be understood, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word “may” is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words “include”, “including”, and “includes” mean including, but not limited to.
The magnetically susceptible materials 115, 125, 135 may be materials, which are not magnets, but are susceptible to magnetic fields, such as ferromagnetic materials. As such, magnetically susceptible materials 115, 125, 135 would not interact with each other in the absence of a magnetic field, such as, during daytime, as opposed to permanent magnets that would potentially interact with each other at all times, which may be inappropriate or even deleterious (e.g., during speaking or swallowing) to a person's health. Magnetically susceptible materials 115, 125, 135 may be in the form of plates, discs, spheres, bars, multiple small pieces, mesh and the like. In an alternate embodiment, the magnetically susceptible materials 115, 125, 135 may be replaced with magnets, such as permanent magnets with magnetic fields of fixed strength or variable magnets (e.g., electromagnets) with magnetic fields of variable strength (including zero if not activated).
Magnet 160 is positioned outside the body and lateral to magnetically susceptible material 125, while magnet 170 is positioned outside the body and lateral to magnetically susceptible material 135, and magnet 180 is positioned outside the body and anterior to magnetically susceptible material 115. Magnets 160, 170, 180 may be attached or placed adjacent to the outer skin 151 of a patient with means, such as a neckband or a chin strap. In one embodiment, magnets 160, 170, 180 may be implanted beneath the outer skin surface, such as, beneath the front skin 211 of the cheek 266 for magnet 160, as shown in
Magnet 160 is configured to attract magnetically susceptible material 125 toward magnet 160 so that movement of the lateral pharyngeal wall 120 toward closure of the upper airway 100 may be opposed. Magnet 170 is configured to attract magnetically susceptible material 135 toward magnet 170 so that movement of the lateral pharyngeal wall 130 toward closure of the upper airway 100 may be opposed. Magnet 180 is configured to attract magnetically susceptible material 115 toward magnet 180 so that movement of the anterior pharyngeal wall 110 toward closure of the upper airway 100 may be opposed. In this manner, the cross sectional dimensions (e.g., the length or width) of the upper airway 100 may be increased or prevented from decreasing, thereby allowing patency of the upper airway 100 to be maintained.
Force fields between magnet 160 and magnetically susceptible material 125 and between magnet 170 and magnetically susceptible material 135 act to keep the soft tissue of the lateral pharyngeal walls 120, 130 from collapsing. Force fields between magnet 180 and magnetically susceptible material 115 act to keep the soft tissue of the anterior pharyngeal wall 110 from collapsing toward the posterior pharyngeal wall 140.
Magnets 315, 325, 335, 345 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electro-magnets, with magnetic fields of variable strength (including zero if not activated).
Magnets 315, 325, 335, 345 are oriented such that the same magnetic poles of the magnets 315, 325, 335, 345 face each other, e.g., north poles facing other north poles. In operation, magnets 315, 325, 335, 345 are configured to repel each other, thereby opposing closure of the upper airway 300 without the use of external magnets.
Magnets 425, 435 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electromagnets, with magnetic fields of variable strength (including zero if not activated). Magnets 425, 435 are oriented such that the same magnetic poles of the magnets 425, 435 face each other, e.g., north pole facing other north pole. In operation, magnets 425, 435 are configured to repel each other, thereby opposing closure of the upper airway 400 without the use of external magnets.
The system 550 further includes magnets 560 and 570 disposed inside the upper airway 500. Magnet 560 is disposed across from magnet 525, while magnet 570 is disposed across from magnet 535. The magnetic poles of magnets 560, 570 are oriented such that magnets 560, 570 repel magnets 525, 535, respectively, thereby opposing closure of the upper airway 500 without the use of external magnets. Magnets 560, 570 may be attached to or held in place by a removable apparatus 580, such as a mouthpiece.
Each magnet or magnetically susceptible material described herein may comprise more than one magnet or magnetically susceptible material. Although embodiments of the invention have been described with reference to two or four magnetically susceptible materials or magnets, embodiments of the invention also contemplate other combinations or numbers of magnets and magnetically susceptible materials. Although embodiments of the invention have been described with reference to treating sleep-related breathing disorders, such as sleep apnea or snoring, embodiments of the invention also contemplate other applications where passageway or airway patency is required. For example, the magnets or magnetically susceptible materials may be inserted or attached through a body aperture, such as the vagina, the rectum, the urinary passage and the like.
While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow.
This application claims benefit of U.S. provisional patent application Ser. No. 60/415,995, filed Oct. 4, 2002, which is herein incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4978323 | Freedman | Dec 1990 | A |
5015538 | Krause et al. | May 1991 | A |
5117816 | Shapiro et al. | Jun 1992 | A |
5176618 | Freedman | Jan 1993 | A |
5199424 | Sullivan et al. | Apr 1993 | A |
5245995 | Sullivan et al. | Sep 1993 | A |
5268082 | Oguro et al. | Dec 1993 | A |
5284161 | Karell | Feb 1994 | A |
5479944 | Petruson | Jan 1996 | A |
5509888 | Miller | Apr 1996 | A |
5522382 | Sullivan et al. | Jun 1996 | A |
5551418 | Estes et al. | Sep 1996 | A |
5823187 | Estes et al. | Oct 1998 | A |
5873363 | Esmailzadeh | Feb 1999 | A |
RE36120 | Karell | Mar 1999 | E |
5901704 | Estes et al. | May 1999 | A |
5904141 | Estes et al. | May 1999 | A |
5970975 | Estes et al. | Oct 1999 | A |
5980998 | Sharma et al. | Nov 1999 | A |
5988171 | Sohn et al. | Nov 1999 | A |
6092523 | Belfer | Jul 2000 | A |
6098629 | Johnson et al. | Aug 2000 | A |
6109852 | Shahinpoor et al. | Aug 2000 | A |
6190893 | Shastri et al. | Feb 2001 | B1 |
6212435 | Lattner et al. | Apr 2001 | B1 |
6250307 | Conrad et al. | Jun 2001 | B1 |
6257234 | Sun | Jul 2001 | B1 |
6376971 | Pelrine et al. | Apr 2002 | B1 |
6379393 | Mavroidis et al. | Apr 2002 | B1 |
6390096 | Conrad et al. | May 2002 | B1 |
6401717 | Conrad et al. | Jun 2002 | B1 |
6408851 | Karell | Jun 2002 | B1 |
6415796 | Conrad et al. | Jul 2002 | B1 |
6431174 | Knudson et al. | Aug 2002 | B1 |
6439238 | Brenzel et al. | Aug 2002 | B1 |
6450169 | Conrad et al. | Sep 2002 | B1 |
6453905 | Conrad et al. | Sep 2002 | B1 |
6454803 | Romo, III | Sep 2002 | B1 |
6467485 | Schmidt | Oct 2002 | B1 |
6475639 | Shahinpoor et al. | Nov 2002 | B1 |
6502574 | Stevens et al. | Jan 2003 | B1 |
6513530 | Knudson et al. | Feb 2003 | B1 |
6513531 | Knudson et al. | Feb 2003 | B1 |
6514237 | Maseda | Feb 2003 | B1 |
6516806 | Knudson et al. | Feb 2003 | B1 |
6523541 | Knudson et al. | Feb 2003 | B1 |
6523542 | Knudson et al. | Feb 2003 | B1 |
6523543 | Conrad et al. | Feb 2003 | B1 |
6529777 | Holmstrom et al. | Mar 2003 | B1 |
6545384 | Pelrine et al. | Apr 2003 | B1 |
6546936 | Knudson et al. | Apr 2003 | B1 |
6569654 | Shastri et al. | May 2003 | B1 |
6578580 | Conrad et al. | Jun 2003 | B1 |
6583533 | Pelrine et al. | Jun 2003 | B1 |
6586859 | Kornbluh et al. | Jul 2003 | B1 |
6601584 | Knudson et al. | Aug 2003 | B1 |
6601585 | Conrad et al. | Aug 2003 | B1 |
6618627 | Lattner et al. | Sep 2003 | B1 |
6619290 | Zacco | Sep 2003 | B1 |
6626181 | Knudson et al. | Sep 2003 | B1 |
6628040 | Pelrine et al. | Sep 2003 | B1 |
6629527 | Estes et al. | Oct 2003 | B1 |
6634362 | Conrad et al. | Oct 2003 | B1 |
6636767 | Knudson et al. | Oct 2003 | B1 |
6664718 | Pelrine et al. | Dec 2003 | B1 |
6667825 | Lu et al. | Dec 2003 | B1 |
6679836 | Couvillon, Jr. | Jan 2004 | B1 |
6707236 | Pelrine et al. | Mar 2004 | B1 |
6742524 | Knudson et al. | Jun 2004 | B1 |
6748951 | Schmidt | Jun 2004 | B1 |
6749556 | Banik | Jun 2004 | B1 |
6768246 | Pelrine et al. | Jul 2004 | B1 |
6770027 | Banik et al. | Aug 2004 | B1 |
6781284 | Pelrine et al. | Aug 2004 | B1 |
6812624 | Pei et al. | Nov 2004 | B1 |
6835173 | Couvillon, Jr. | Dec 2004 | B1 |
6955172 | Nelson et al. | Oct 2005 | B1 |
20020173848 | Sachs | Nov 2002 | A1 |
20030015198 | Hecke et al. | Jan 2003 | A1 |
20030140930 | Knudson et al. | Jul 2003 | A1 |
20030149445 | Knudson et al. | Aug 2003 | A1 |
20030149488 | Metzger et al. | Aug 2003 | A1 |
20030192556 | Conrad et al. | Oct 2003 | A1 |
20030196669 | Conrad et al. | Oct 2003 | A1 |
20040016433 | Estes et al. | Jan 2004 | A1 |
20040019368 | Lattner et al. | Jan 2004 | A1 |
20040020497 | Knudson et al. | Feb 2004 | A1 |
20040020498 | Knudson et al. | Feb 2004 | A1 |
20040045555 | Nelson et al. | Mar 2004 | A1 |
20040045556 | Nelson et al. | Mar 2004 | A1 |
20040073272 | Knudson et al. | Apr 2004 | A1 |
20040134491 | Pflueger et al. | Jul 2004 | A1 |
20040139975 | Nelson et al. | Jul 2004 | A1 |
20040149290 | Nelson et al. | Aug 2004 | A1 |
20040172054 | Metzger et al. | Sep 2004 | A1 |
20050004417 | Nelson et al. | Jan 2005 | A1 |
20050115572 | Brooks et al. | Jun 2005 | A1 |
20050121039 | Brooks et al. | Jun 2005 | A1 |
20050159637 | Nelson et al. | Jul 2005 | A9 |
20050199248 | Pflueger et al. | Sep 2005 | A1 |
20050268919 | Knudson et al. | Dec 2005 | A1 |
20050284485 | Nelson et al. | Dec 2005 | A9 |
Number | Date | Country |
---|---|---|
4412190 | Oct 1995 | DE |
0312368 | Apr 1989 | EP |
0743076 | Nov 1996 | EP |
1306104 | May 2003 | EP |
WO 8810108 | Dec 1988 | WO |
WO 9611653 | Apr 1996 | WO |
WO 9726039 | Jul 1997 | WO |
WO 0119301 | Mar 2001 | WO |
WO 0213738 | Feb 2002 | WO |
WO 02056876 | Jul 2002 | WO |
WO 02076341 | Oct 2002 | WO |
WO 02076352 | Oct 2002 | WO |
WO 02076353 | Oct 2002 | WO |
WO 02076354 | Oct 2002 | WO |
WO 03041612 | May 2003 | WO |
WO 03065947 | Aug 2003 | WO |
WO 2004043288 | May 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20040112390 A1 | Jun 2004 | US |
Number | Date | Country | |
---|---|---|---|
60415995 | Oct 2002 | US |